Roles of Podoplanin in Malignant Progression of Tumor

Suzuki, Hiroyuki; Kaneko, Mika K.; Kato, Yukinari

doi:10.3390/cells11030575

Cited by 53 publications

(57 citation statements)

References 200 publications

(246 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We previously established cancer−specific mAbs (CasMabs) targeting to PDPN [ 34 , 35 , 36 , 37 ] and podocalyxin [ 38 ], which are expressed on many cancers, including ESCC [ 39 , 40 , 41 , 42 ]. These CasMabs recognize cancer−specific aberrant glycosylation of the target proteins [ 43 ]. It is worthwhile to develop a cancer−specific anti−CD44 antibody using the CasMab method.…”

Section: Discussionmentioning

confidence: 99%

Development of a Novel Anti−CD44 Monoclonal Antibody for Multiple Applications against Esophageal Squamous Cell Carcinomas

Goto

Suzuki

Tanaka

et al. 2022

IJMS

Self Cite

View full text Add to dashboard Cite

CD44 is a cell surface glycoprotein, which is expressed on normal cells, and overexpressed on cancer cells. CD44 is involved in cell adhesion, migration, proliferation, survival, stemness, and chemo−resistance. Therefore, CD44 is thought to be a promising target for cancer diagnosis and therapy. In this study, we established anti−CD44 monoclonal antibodies (mAbs) by immunizing mice with a CD44 variant (CD44v3−10) ectodomain and screening using enzyme−linked immunosorbent assay. We then characterized them using flow cytometry, Western blotting, and immunohistochemistry. One of the established clones (C44Mab−46; IgG1, kappa) reacted with CD44 standard isoform (CD44s)−overexpressed Chinese hamster ovary−K1 cells (CHO/CD44s) or esophageal squamous cell carcinoma (ESCC) cell lines (KYSE70 and KYSE770). The apparent KD of C44Mab−46 for CHO/CD44s, KYSE70, and KYSE770 was 1.1 × 10−8 M, 4.9 × 10−8 M, and 4.1 × 10−8 M, respectively. C44Mab−46 detected CD44s of CHO/CD44s and KYSE70, and CD44 variants of KYSE770 in Western blot analysis. Furthermore, C44Mab−46 strongly stained the formalin−fixed paraffin−embedded ESCC tissues in immunohistochemistry. Collectively, C44Mab−46 is very useful for detecting CD44 in various applications.

show abstract

Section: Discussionmentioning

confidence: 99%

Development of a Novel Anti−CD44 Monoclonal Antibody for Multiple Applications against Esophageal Squamous Cell Carcinomas

Goto

Suzuki

Tanaka

et al. 2022

IJMS

Self Cite

View full text Add to dashboard Cite

show abstract

“…Moreover, it has been speculated that CLEC-2 depletion did not show severe bleeding tendency, so that to some extent targeting platelet CLEC-2 is a safe treatment strategy (43,46,48). In addition, PDPN is also expressed in tumor stroma, including cancer-associated fibroblasts (CAFs) (49). PDPN-positive CAFs exhibit poor clinical outcomes in cancers of the lung (50), breast (51, 52), pancreas (53), and esophagus (54).…”

Section: Effects Of Taps On Cancer Invasion and Metastasismentioning

confidence: 99%

Platelets in the tumor microenvironment and their biological effects on cancer hallmarks

Chen

Fan

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

The interplay between platelets and tumors has long been studied. It has been widely accepted that platelets could promote tumor metastasis. However, the precise interactions between platelets and tumor cells have not been thoroughly investigated. Although platelets may play complex roles in multiple steps of tumor development, most studies focus on the platelets in the circulation of tumor patients. Platelets in the primary tumor microenvironment, in addition to platelets in the circulation during tumor cell dissemination, have recently been studied. Their effects on tumor biology are gradually figured out. According to updated cancer hallmarks, we reviewed the biological effects of platelets on tumors, including regulating tumor proliferation and growth, promoting cancer invasion and metastasis, inducing vasculature, avoiding immune destruction, and mediating tumor metabolism and inflammation.

show abstract

“…Of the top ten genes by correlation in HNSCC [ 47 ], many were found to have functions that support the known role that CSPG4 plays in cancer pathogenesis, such as cell migration, tissue remodelling and angiogenesis. PDPN encodes a mucin-type TM glycoprotein that has functions in development, immunology, migration, invasion, and metastasis [ 160 , 168 ]. Similarly, PIK3CD, which encodes the delta subunit of PI3K, is a key intracellular mediator of cell growth, proliferation, survival and the EMT [ 169 ].…”

Section: Genes Co-regulated With Cspg4 In Sccsmentioning

confidence: 99%

Chondroitin Sulfate Proteoglycan 4 as a Marker for Aggressive Squamous Cell Carcinoma

Chen

Yong

Zauner

et al. 2022

Cancers

View full text Add to dashboard Cite

Chondroitin sulfate (CS) proteoglycan 4 (CSPG4) is a cell surface proteoglycan that is currently under investigation as a marker of cancer malignancy, and as a potential target of anticancer drug treatment. CSPG4 acts as a driver of tumourigenesis by regulating turnover of the extracellular matrix (ECM) to promote tumour cell invasion, migration as well as inflammation and angiogenesis. While CSPG4 has been widely studied in certain malignancies, such as melanoma, evidence is emerging from global gene expression studies, which suggests a role for CSPG4 in squamous cell carcinoma (SCC). While relatively treatable, lack of widely agreed upon diagnostic markers for SCCs is problematic, especially for clinicians managing certain patients, including those who are aged or infirm, as well as those with underlying conditions such as epidermolysis bullosa (EB), for which a delayed diagnosis is likely lethal. In this review, we have discussed the structure of CSPG4, and quantitatively analysed CSPG4 expression in the tissues and pathologies where it has been identified to determine the usefulness of CSPG4 expression as a diagnostic marker and therapeutic target in management of malignant SCC.

show abstract

Roles of Podoplanin in Malignant Progression of Tumor

Cited by 53 publications

References 200 publications

Development of a Novel Anti−CD44 Monoclonal Antibody for Multiple Applications against Esophageal Squamous Cell Carcinomas

Development of a Novel Anti−CD44 Monoclonal Antibody for Multiple Applications against Esophageal Squamous Cell Carcinomas

Platelets in the tumor microenvironment and their biological effects on cancer hallmarks

Chondroitin Sulfate Proteoglycan 4 as a Marker for Aggressive Squamous Cell Carcinoma

Contact Info

Product

Resources

About